Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response
Abstract
Purpose To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and visual prognosis. Methods This single-center retrospective cohort included 34 nAMD eyes that had received at least three consecutive aflibercept injections at 4-week intervals. Patients followed a 1+pro re nata (PRN) regimen for 12 months post-switch. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, and the prevalence of subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage (SRH) were evaluated. In 13 eyes with baseline SHRM, generalized estimating equations (GEE) were utilized to explore the association of dynamic SHRM height changes and treatment interval adjustments with visual acuity changes. Results A total of 34 eyes were included. CMT dropped significantly after the initial faricimab injection (P = 0.0427). SRF prevalence declined markedly at 6 months, with significant PED and IRF prevalence reductions at 12 months. Among the 11 eyes with baseline SRH, the maximum SRH diameter decreased significantly at month 12 (adjusted P = 0.0039). No significant change was detected in BCVA. Median treatment intervals lengthened from 4.5 to 8.0 weeks (P = 0.017). In 13 eyes with baseline SHRM, SHRM reduction was associated with contemporaneous treatment-interval prolongation (B = −3.299 weeks per 100-μm increase; P < 0.001), but not with subsequent injection intervals or concurrent visual-acuity changes. Conclusion Switching to faricimab was associated with overall anatomical improvements and prolonged treatment intervals among pretreated nAMD eyes, while visual gains remained limited. However, complete anatomical resolution was not achieved in all patients. Dynamic changes in SHRM height may represent an exploratory imaging feature associated with treatment interval changes, however, its prospective predictive value and clinical utility remain to be validated.